Vincenzo LA Mura, Massimo Colombo, Graham R Foster, Paolo Angeli, Wolfgang Miesbach, Robert Klamroth, Glenn F Pierce, Brian O'Mahony, Ming Y Lim, Virginia Hernandez-Gea, Michael Makris, Flora Peyvandi
People with bleeding disorders (PWBD) have been exposed to the risk of developing chronic viral hepatitis and cirrhosis after replacement therapy. At today, the advent of new pharmacological strategies for the control of hemostasis and the efficacious antiviral therapies against HCV and HBV have significantly reduced this risk. However, the real success for liver health in this clinical setting is based on other risk factors, among them, the severity of liver disease at time of HBV/HCV antiviral therapy and the exposure to highly prevalent factors of chronic liver damage (e...
September 11, 2024: Journal of Thrombosis and Haemostasis: JTH